{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T02:58:19Z","timestamp":1780714699089,"version":"3.54.1"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.pcad.2024.01.013","type":"journal-article","created":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T23:46:07Z","timestamp":1705794367000},"page":"113-124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Advances in the diagnosis and treatment of transthyretin amyloid cardiomyopathy"],"prefix":"10.1016","volume":"82","author":[{"given":"Joban","family":"Vaishnav","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcad.2024.01.013_bb0005","first-page":"e7","article-title":"Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association","volume":"142","author":"Kittleson Michelle","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2024.01.013_bb0010","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1161\/CIRCULATIONAHA.120.050498","article-title":"Myocardial gene expression signatures in human heart failure with preserved ejection fraction","volume":"143","author":"Hahn","year":"2021","journal-title":"Circulation."},{"key":"10.1016\/j.pcad.2024.01.013_bb0015","first-page":"113","article-title":"Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC","volume":"2","author":"Mohammed","year":"2014","journal-title":"Heart Failure"},{"key":"10.1016\/j.pcad.2024.01.013_bb0020","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation."},{"key":"10.1016\/j.pcad.2024.01.013_bb0025","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1161\/CIRCRESAHA.121.318187","article-title":"Pathophysiology and therapeutic approaches to cardiac amyloidosis","volume":"128","author":"Griffin","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.pcad.2024.01.013_bb0030","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2024.01.013_bb0035","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","article-title":"Patisiran treatment in patients with transthyretin cardiac amyloidosis","volume":"389","author":"Maurer","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2024.01.013_bb0040","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2024.01.013_bb0045","article-title":"ATTR Amyloidosis: Current and Emerging Management Strategies: JACC: CardioOncology State-of-the-Art Review","author":"Griffin","year":"2021","journal-title":"JACC: CardioOncol"},{"key":"10.1016\/j.pcad.2024.01.013_bb0050","series-title":"Endomyocardial Biopsy Characterization of Heart Failure With Preserved Ejection Fraction and Prevalence of Cardiac Amyloidosis","first-page":"712","volume":"8","author":"Hahn","year":"2020"},{"key":"10.1016\/j.pcad.2024.01.013_bb0055","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (transthyretin amyloid outcome survey)","volume":"68","author":"Maurer","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2024.01.013_bb0060","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis","volume":"140","author":"Lane","year":"2019","journal-title":"Circulation."},{"key":"10.1016\/j.pcad.2024.01.013_bb0065","series-title":"Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans","first-page":"733","volume":"19","author":"Buxbaum","year":"2017"},{"key":"10.1016\/j.pcad.2024.01.013_bb0070","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2019.17935","article-title":"Association of the V122I hereditary transthyretin amyloidosis genetic variant with heart failure among individuals of African or Hispanic\/Latino ancestry","volume":"322","author":"Damrauer","year":"2019","journal-title":"JAMA."},{"key":"10.1016\/j.pcad.2024.01.013_bb0075","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.028973","article-title":"Clinical penetrance of the transthyretin V122I variant in older black patients with heart failure: the SCAN-MP (screening for cardiac amyloidosis with nuclear imaging in minority populations) study","volume":"12","author":"Madhani","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.pcad.2024.01.013_bb0080","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1185\/03007995.2012.754348","article-title":"THAOS - the transthyretin amyloidosis outcomes survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis","volume":"29","author":"Coelho","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.pcad.2024.01.013_bb0085","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2024.01.013_bb0090","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2024.01.013_bb0095","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1080\/13506129.2018.1498782","article-title":"Seven factors predict a delayed diagnosis of cardiac amyloidosis","volume":"25","author":"Bishop","year":"2018","journal-title":"Amyloid."},{"key":"10.1016\/j.pcad.2024.01.013_bb0100","first-page":"709","article-title":"Screening for transthyretin amyloid cardiomyopathy in everyday practice","volume":"7","author":"Witteles","year":"2019","journal-title":"JACC: Heart Failure"},{"key":"10.1016\/j.pcad.2024.01.013_bb0105","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/ejhf.2533","article-title":"Incidence and risk factors for pacemaker implantation in light-chain and transthyretin cardiac amyloidosis","volume":"24","author":"Porcari","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.pcad.2024.01.013_bb0110","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement","volume":"38","author":"Casta\u00f1o","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2024.01.013_bb0115","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.787618","article-title":"Multimodality imaging in the evaluation and prognostication of cardiac amyloidosis","volume":"9","author":"Scheel","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.pcad.2024.01.013_bb0120","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.amjcard.2014.07.026","article-title":"Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis","volume":"114","author":"Cyrille","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2024.01.013_bb0125","first-page":"914","article-title":"Assessing the onset and characteristics of orthostatic hypotension in patients with transthyretin amyloidosis from the transthyretin amyloidosis outcomes survey (THAOS)","volume":"381","author":"Gonzalez-Duarte","year":"2017","journal-title":"Abstracts World Congress Neurol"},{"key":"10.1016\/j.pcad.2024.01.013_bb0130","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jacc.2019.04.054","article-title":"Association of Carpal Tunnel Syndrome with Amyloidosis, heart failure, and adverse cardiovascular outcomes","volume":"74","author":"Fosb\u00f8l Emil","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2024.01.013_bb0135","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.jacc.2018.07.092","article-title":"Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release","volume":"72","author":"Sperry","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2024.01.013_bb0140","series-title":"Screening for Cardiac Amyloidosis 5 to 15 Years After Surgery for Bilateral Carpal Tunnel Syndrome","first-page":"967","volume":"80","author":"Westin","year":"2022"},{"key":"10.1016\/j.pcad.2024.01.013_bb0145","unstructured":"Debonnaire P, Claeys M, De Paepe P, Christiaen E, Geerts B, De Geeter F, Trenson S, Hoste D, Van Droogenbroeck J, Verhoeven K, et al. Prospective screening for transthyretin cardiac amyloidosis in spinal stenosis surgery patients. JACC Cardio Oncol."},{"key":"10.1016\/j.pcad.2024.01.013_bb0150","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1007\/s12350-019-01760-6","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging","author":"Dorbala","year":"2019","journal-title":"J Nucl Cardiol United States"},{"key":"10.1016\/j.pcad.2024.01.013_bb0155","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","article-title":"Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy","volume":"46","author":"Perugini","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2024.01.013_bb0160","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"2023 ACC expert consensus decision pathway on comprehensive multidisciplinary Care for the Patient with Cardiac Amyloidosis: a report of the American College of Cardiology Solution set Oversight Committee","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2024.01.013_bb0165","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the Management of Heart Failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation."},{"key":"10.1016\/j.pcad.2024.01.013_bb0170","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.008225","article-title":"Avoiding catastrophe","volume":"14","author":"Witteles","year":"2021","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.pcad.2024.01.013_bb0175","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2\u2014evidence base and standardized methods of imaging","volume":"14","author":"Dorbala","year":"2021","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.pcad.2024.01.013_bb0180","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1093\/eurheartj\/ehx047","article-title":"Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis","volume":"38","author":"Quarta","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2024.01.013_bb0185","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1080\/13506129.2017.1324418","article-title":"Genetic testing improves identification of transthyretin amyloid (ATTR) subtype in cardiac amyloidosis","volume":"24","author":"Brown","year":"2017","journal-title":"Amyloid."},{"key":"10.1016\/j.pcad.2024.01.013_bb0190","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1001\/jamacardio.2022.2455","article-title":"Assessment of the diagnostic yield of combined cardiomyopathy and arrhythmia genetic testing","volume":"7","author":"Dellefave-Castillo","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.pcad.2024.01.013_bb0195","first-page":"10","article-title":"Multiple gene variants in hypertrophic cardiomyopathy in the era of next-generation sequencing","author":"Burns","year":"2017","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.pcad.2024.01.013_bb0200","doi-asserted-by":"crossref","DOI":"10.1161\/HCG.0000000000000067","article-title":"Genetic testing for inherited cardiovascular diseases: a scientific statement from the American Heart Association","volume":"13","author":"Musunuru","year":"2020","journal-title":"Circ Genom Precis Med"},{"issue":"suppl 1","key":"10.1016\/j.pcad.2024.01.013_bb0205","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1097\/WCO.0000000000000290","article-title":"Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis","volume":"29","author":"Obici","year":"2016","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.pcad.2024.01.013_bb0210","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1542\/peds.2012-3680","article-title":"Ethical and policy issues in genetic testing and screening of children","volume":"131","year":"2013","journal-title":"Pediatrics."},{"key":"10.1016\/j.pcad.2024.01.013_bb0215","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/eurheartj\/ehs123","article-title":"Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective","volume":"34","author":"Rapezzi","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2024.01.013_bb0220","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/13506120802193720","article-title":"Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population","volume":"15","author":"Hellman","year":"2008","journal-title":"Amyloid."},{"key":"10.1016\/j.pcad.2024.01.013_bb0225","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1038\/ejhg.2010.36","article-title":"TTR familial amyloid polyneuropathy: does a mitochondrial polymorphism entirely explain the parent-of-origin difference in penetrance?","volume":"18","author":"Bona\u00efti","year":"2010","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.pcad.2024.01.013_bb0230","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1080\/13506129.2020.1841623","article-title":"New data on the genetic profile and penetrance of hereditary Val30Met transthyretin amyloidosis in Sweden","volume":"28","author":"Gorram","year":"2021","journal-title":"Amyloid."},{"key":"10.1016\/j.pcad.2024.01.013_bb0235","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000490553","article-title":"Epidemiology of transthyretin familial amyloid polyneuropathy in Portugal: a Nationwide study","volume":"51","author":"In\u00eas","year":"2018","journal-title":"Neuroepidemiology."},{"key":"10.1016\/j.pcad.2024.01.013_bb0240","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1136\/jnnp-2013-305383","article-title":"Overcoming artefact: anticipation in 284 Portuguese kindreds with familial amyloid polyneuropathy (FAP) ATTRV30M","volume":"85","author":"Lemos","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.pcad.2024.01.013_bb0245","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ahj.2020.12.009","article-title":"Management of heart failure in cardiac amyloidosis using an ambulatory diuresis clinic","volume":"233","author":"Vaishnav","year":"2020","journal-title":"Am Heart J"},{"key":"10.1016\/j.pcad.2024.01.013_bb0250","first-page":"65","article-title":"Efficacy of intravenous furosemide versus a novel, pH-neutral furosemide formulation administered subcutaneously in outpatients with worsening heart failure","volume":"6","author":"Gilotra Nisha","year":"2018","journal-title":"JACC: Heart Failure"},{"key":"10.1016\/j.pcad.2024.01.013_bb0255","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jchf.2021.06.007","article-title":"Spironolactone in patients with an echocardiographic HFpEF phenotype suggestive of cardiac amyloidosis: results from TOPCAT","volume":"9","author":"Sperry","year":"2021","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.pcad.2024.01.013_bb0260","first-page":"2893","article-title":"Conventional heart failure therapy in cardiac ATTR amyloidosis","volume":"44","author":"Ioannou","year":"2023"},{"key":"10.1016\/j.pcad.2024.01.013_bb0265","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"he Lancet"},{"key":"10.1016\/j.pcad.2024.01.013_bb0270","first-page":"1243","article-title":"SGLT2i in patients with transthyretin cardiac amyloidosis, a well-tolerated option for heart failure treatment? Results from a small, real-world, patients series","volume":"17","author":"Zampieri","year":"2022"},{"key":"10.1016\/j.pcad.2024.01.013_bb0275","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ehf2.14188","article-title":"SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to dapagliflozin","volume":"10","author":"Dobner","year":"2023","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.pcad.2024.01.013_bb0280","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1161\/CIRCHEARTFAILURE.109.910455","article-title":"Pressure-volume relationships in patients with transthyretin (ATTR) cardiac amyloidosis secondary to V122I mutations and wild-type transthyretin: transthyretin cardiac amyloid study (TRACS)","volume":"4","author":"Bhuiyan","year":"2011","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.pcad.2024.01.013_bb0285","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.022859","article-title":"Lack of association between Neurohormonal blockade and survival in transthyretin cardiac amyloidosis","volume":"10","author":"Cheng","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.pcad.2024.01.013_bb0290","series-title":"Management of Arrhythmias in Cardiac Amyloidosis","first-page":"351","volume":"6","author":"Giancaterino","year":"2020"},{"key":"10.1016\/j.pcad.2024.01.013_bb0295","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.jacep.2020.04.019","article-title":"Atrial fibrillation in transthyretin cardiac amyloidosis: predictors, prevalence, and efficacy of rhythm control strategies","volume":"6","author":"Donnellan","year":"2020","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.pcad.2024.01.013_bb0300","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.amjcard.2020.07.034","article-title":"Digoxin use in cardiac amyloidosis","volume":"133","author":"Donnelly","year":"2020","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2024.01.013_bb0305","series-title":"No Association Between CHADS-VASc Score and Left Atrial Appendage Thrombus in Patients With Transthyretin Amyloidosis","first-page":"1473","volume":"5","author":"Donnellan","year":"2019"},{"key":"10.1016\/j.pcad.2024.01.013_bb0310","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jacc.2018.10.079","article-title":"Direct current cardioversion of atrial arrhythmias in adults with cardiac amyloidosis","volume":"73","author":"El-Am","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2024.01.013_bb0315","series-title":"Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT])","first-page":"146","volume":"148","author":"Miller","year":"2021"},{"key":"10.1016\/j.pcad.2024.01.013_bb0320","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/pace.14023","article-title":"Primary prevention implantable cardioverter-defibrillators in transthyretin cardiac amyloidosis","volume":"43","author":"Donnellan","year":"2020","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.pcad.2024.01.013_bb0325","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/jce.12123","article-title":"Implantable cardioverter defibrillators in patients with cardiac amyloidosis","volume":"24","author":"Lin","year":"2013","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.pcad.2024.01.013_bb0330","first-page":"e301","article-title":"HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy","volume":"16","author":"Towbin","year":"2019"},{"key":"10.1016\/j.pcad.2024.01.013_bb0335","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/CIRCULATIONAHA.119.045093","article-title":"Cost-effectiveness of Tafamidis therapy for transthyretin amyloid cardiomyopathy","volume":"141","author":"Kazi","year":"2020","journal-title":"Circulation."},{"key":"10.1016\/j.pcad.2024.01.013_bb0340","doi-asserted-by":"crossref","first-page":"7862","DOI":"10.1021\/acs.jmedchem.8b00817","article-title":"Enthalpy-driven stabilization of transthyretin by AG10 mimics a naturally occurring genetic variant that protects from transthyretin amyloidosis","volume":"61","author":"Miller","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.pcad.2024.01.013_bb0345","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1080\/13506129.2020.1808783","article-title":"Blinded potency comparison of transthyretin kinetic stabilisers by subunit exchange in human plasma","volume":"28","author":"Nelson","year":"2021","journal-title":"Amyloid."},{"key":"10.1016\/j.pcad.2024.01.013_bb0350","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial","volume":"310","author":"Berk","year":"2013","journal-title":"Jama."},{"key":"10.1016\/j.pcad.2024.01.013_bb0355","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2024.01.013_bb0360","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of Patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis: analysis of the APOLLO study","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation."},{"key":"10.1016\/j.pcad.2024.01.013_bb0365","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1080\/13506129.2022.2091985","article-title":"Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial","volume":"30","author":"Adams","year":"2023","journal-title":"Amyloid."},{"key":"10.1016\/j.pcad.2024.01.013_bb0370","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2024.01.013_bb0375","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1001\/jama.2023.18688","article-title":"Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy","volume":"330","author":"Coelho","year":"2023","journal-title":"JAMA."},{"key":"10.1016\/j.pcad.2024.01.013_bb0380","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N Engl J Med"},{"issue":"Supplement_2","key":"10.1016\/j.pcad.2024.01.013_bb0385","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehac544.1767","article-title":"NNC6019\u20130001 a humanized monoclonal antibody, in patients with transthyretin amyloid cardiomyopathy (ATTR-CM): rationale and study design of a phase 2, randomized, placebo-controlled trial","volume":"43","author":"Fontana","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2024.01.013_bb0390","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2303765","article-title":"Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid","volume":"389","author":"Garcia-Pavia","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2024.01.013_bb0395","first-page":"461","article-title":"Outcomes in patients with cardiac amyloidosis undergoing heart transplantation. JACC","volume":"8","author":"Barrett Christopher","year":"2020","journal-title":"Heart Fail"},{"key":"10.1016\/j.pcad.2024.01.013_bb0400","doi-asserted-by":"crossref","first-page":"11645","DOI":"10.1038\/s41598-021-91113-6","article-title":"Association of the transthyretin variant V122I with polyneuropathy among individuals of African ancestry","volume":"11","author":"Parker","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.pcad.2024.01.013_bb0405","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s13023-022-02359-w","article-title":"Clinical and genetic profile of patients enrolled in the transthyretin amyloidosis outcomes survey (THAOS): 14-year update","volume":"17","author":"Dispenzieri","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.pcad.2024.01.013_bb0410","doi-asserted-by":"crossref","first-page":"e2036","DOI":"10.1212\/WNL.0000000000207158","article-title":"Phenotypes associated with the Val122Ile, Leu58His, and late-onset Val30Met variants in patients with hereditary transthyretin amyloidosis","volume":"100","author":"Zampino","year":"2023","journal-title":"Neurology."},{"key":"10.1016\/j.pcad.2024.01.013_bb0415","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jns.2008.02.019","article-title":"Epidemiology of familial amyloid polyneuropathy in Japan: identification of a novel endemic focus","volume":"270","author":"Kato-Motozaki","year":"2008","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.pcad.2024.01.013_bb0420","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/archneur.59.11.1771","article-title":"Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: early- vs late-onset form","volume":"59","author":"Koike","year":"2002","journal-title":"Arch Neurol"},{"key":"10.1016\/j.pcad.2024.01.013_bb0425","doi-asserted-by":"crossref","DOI":"10.1136\/jmg.40.11.e120","article-title":"Genetic study of transthyretin amyloid neuropathies: carrier risks among French and Portuguese families","volume":"40","author":"Plant\u00e9-Bordeneuve","year":"2003","journal-title":"J Med Genet"},{"key":"10.1016\/j.pcad.2024.01.013_bb0430","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s40120-021-00258-z","article-title":"Characteristics of patients with late- vs. early-onset Val30Met transthyretin amyloidosis from the transthyretin amyloidosis outcomes survey (THAOS)","volume":"10","author":"Waddington-Cruz","year":"2021","journal-title":"Neurol Ther"},{"key":"10.1016\/j.pcad.2024.01.013_bb0435","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1136\/jnnp.59.1.45","article-title":"Familial amyloid polyneuropathy (TTR ala 60) in north West Ireland: a clinical, genetic, and epidemiological study","volume":"59","author":"Reilly","year":"1995","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.pcad.2024.01.013_bb0440","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1046\/j.1529-8027.2001.01007-24.x","article-title":"The PHE64LEU variant of TTR is associated with a late-onset form of familial Amyloidotic polyneuropathy dominated by motor involvement","volume":"6","author":"Ferrarini","year":"2001","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.pcad.2024.01.013_bb0445","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.jcmg.2019.10.015","article-title":"Low sensitivity of bone scintigraphy in detecting Phe64Leu mutation-related transthyretin cardiac amyloidosis","volume":"13","author":"Musumeci","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.pcad.2024.01.013_bb0450","series-title":"A new staging system for cardiac transthyretin amyloidosis","first-page":"2799","volume":"39","author":"Gillmore","year":"2018"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062024000136?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062024000136?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:23:17Z","timestamp":1758500597000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062024000136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":90,"alternative-id":["S0033062024000136"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2024.01.013","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in the diagnosis and treatment of transthyretin amyloid cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2024.01.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}